Germline polymorphisms in myeloid-associated genes are not associated with survival in glioma patients
- PMID: 28965162
- PMCID: PMC5756111
- DOI: 10.1007/s11060-017-2622-6
Germline polymorphisms in myeloid-associated genes are not associated with survival in glioma patients
Abstract
Immune cells of myeloid origin, including microglia, macrophages, and myeloid-derived suppressor cells adopt immunosuppressive phenotypes that support gliomagenesis. Here, we tested an a priori hypothesis that single nucleotide polymorphisms (SNPs) in genes related to glioma-associated myeloid cell regulation and function are also associated with patient survival after glioma diagnosis. Subjects for this study were 992 glioma patients treated at The University of Texas MD Anderson Cancer Center in Houston, Texas between 1992 and 2008. Haplotype-tagging SNPs in 91 myeloid-associated genes were analyzed for association with survival by Cox regression. Individual SNP- and gene-based tests were performed separately in glioblastoma (WHO grade IV, n = 511) and lower-grade glioma (WHO grade II-III, n = 481) groups. After adjustment for multiple testing, no myeloid-associated gene variants were significantly associated with survival in glioblastoma. Two SNPs, rs147960238 in CD163 (p = 2.2 × 10-5) and rs17138945 in MET (p = 5.6 × 10-5) were significantly associated with survival of patients with lower-grade glioma. However, these associations were not confirmed in an independent analysis of 563 lower-grade glioma cases from the University of California at San Francisco Adult Glioma Study (p = 0.65 and p = 0.41, respectively). The results of this study do not support a role for inherited polymorphisms in myeloid-associated genes in affecting survival of patients diagnosed with glioblastoma or lower-grade glioma.
Keywords: Genetic polymorphism; Glioblastoma; Glioma; Glioma-associated myeloid cells; Immune suppression; Survival.
Figures

Similar articles
-
Polymorphisms in the interleukin-4 receptor gene are associated with better survival in patients with glioblastoma.Clin Cancer Res. 2008 Oct 15;14(20):6640-6. doi: 10.1158/1078-0432.CCR-07-4681. Clin Cancer Res. 2008. PMID: 18927306 Free PMC article.
-
Genetic variations in EGF and EGFR and glioblastoma outcome.Neuro Oncol. 2010 Aug;12(8):815-21. doi: 10.1093/neuonc/noq018. Epub 2010 Mar 2. Neuro Oncol. 2010. PMID: 20197289 Free PMC article.
-
SSBP2 variants are associated with survival in glioblastoma patients.Clin Cancer Res. 2012 Jun 1;18(11):3154-62. doi: 10.1158/1078-0432.CCR-11-2778. Epub 2012 Apr 3. Clin Cancer Res. 2012. PMID: 22472174 Free PMC article.
-
The prognostic significance of CDKN2A homozygous deletion in IDH-mutant lower-grade glioma and glioblastoma: a systematic review of the contemporary literature.J Neurooncol. 2020 Jun;148(2):221-229. doi: 10.1007/s11060-020-03528-2. Epub 2020 May 8. J Neurooncol. 2020. PMID: 32385699
-
Familial aggregation of glioma: a pooled analysis.Am J Epidemiol. 2010 Nov 15;172(10):1099-107. doi: 10.1093/aje/kwq261. Epub 2010 Sep 21. Am J Epidemiol. 2010. PMID: 20858744 Free PMC article. Review.
Cited by
-
Explicating the Pivotal Pathogenic, Diagnostic, and Therapeutic Biomarker Potentials of Myeloid-Derived Suppressor Cells in Glioblastoma.Dis Markers. 2020 Nov 4;2020:8844313. doi: 10.1155/2020/8844313. eCollection 2020. Dis Markers. 2020. PMID: 33204365 Free PMC article. Review.
-
Prevalence of pathogenic germline variants in adult-type diffuse glioma.Neurooncol Pract. 2023 Jun 21;10(5):482-490. doi: 10.1093/nop/npad033. eCollection 2023 Oct. Neurooncol Pract. 2023. PMID: 37720399 Free PMC article.
-
Myeloid-Derived Suppressive Cells Promote B cell-Mediated Immunosuppression via Transfer of PD-L1 in Glioblastoma.Cancer Immunol Res. 2019 Dec;7(12):1928-1943. doi: 10.1158/2326-6066.CIR-19-0240. Epub 2019 Sep 17. Cancer Immunol Res. 2019. PMID: 31530559 Free PMC article.
References
-
- Prosniak M, Harshyne LA, Andrews DW, Kenyon LC, Bedelbaeva K, Apanasovich TV, Heber-Katz E, Curtis MT, Cotzia P, Hooper DC. Glioma grade is associated with the accumulation and activity of cells bearing M2 monocyte markers. Clin Cancer Res. 2013;19:3776–3786. - PubMed
-
- Umemura N, Saio M, Suwa T, Kitoh Y, Bai J, Nonaka K, Ouyang GF, Okada M, Balazs M, Adany R, Shibata T, Takami T. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J Leukoc Biol. 2008;83:1136–1144. - PubMed
MeSH terms
Grants and funding
- R01 CA139020/CA/NCI NIH HHS/United States
- R01 CA120813/CA/NCI NIH HHS/United States
- P50CA097257/NH/NIH HHS/United States
- K07 CA181480/CA/NCI NIH HHS/United States
- UL1 RR024131/RR/NCRR NIH HHS/United States
- R01 CA070917/NH/NIH HHS/United States
- P50 CA097257/CA/NCI NIH HHS/United States
- HHSN261201000035I/CA/NCI NIH HHS/United States
- R01 CA207360/CA/NCI NIH HHS/United States
- U58 DP003862/DP/NCCDPHP CDC HHS/United States
- P50 CA127001/CA/NCI NIH HHS/United States
- R01 CA120813/NH/NIH HHS/United States
- R01 CA052689/CA/NCI NIH HHS/United States
- HHSN261201000140C/CA/NCI NIH HHS/United States
- K07 CA181480/NH/NIH HHS/United States
- P50 CA127001/NH/NIH HHS/United States
- R01 CA139020/NH/NIH HHS/United States
- R01 CA119215/NH/NIH HHS/United States
- R01 CA070917/CA/NCI NIH HHS/United States
- R01CA139020/NH/NIH HHS/United States
- HHSN261201000035C/PC/NCI NIH HHS/United States
- HHSN261201000034C/CA/NCI NIH HHS/United States
- R01 CA119215/CA/NCI NIH HHS/United States
- R01CA52689/NH/NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous